Intercept's NASH Drug Prospects Plummet, Stock Tumbles.
TL;DR Summary
The FDA advisory panel's negative vote on Intercept Pharmaceuticals' drug obeticholic acid seems to end hopes for FDA-approved drugs to treat NASH, a liver condition. However, other drugs are still in the pipeline for approval.
- NASH Drugs Suffer Another Blow, but Hope Remains Barron's
- ICPT Stock Crashes As NASH Rejection Appears Imminent Investor's Business Daily
- Biotech Hits Record Low on FDA Curveball Schaeffers Research
- Intercept (ICPT) NASH Treatment Fails to Get GIDAC Recommendation Yahoo Finance
- Intercept tumbles on concerns over prospects of fatty liver disease drug Reuters
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
0 min
vs 1 min read
Condensed
56%
80 → 35 words
Want the full story? Read the original article
Read on Barron's